Read your latest personalised notifications
No account yet? Start here
Don't miss out
Ok, got it
Stockholm, Sweden, 29 August: Ivabradine, a selective If inhibitor already investigated for its effects in coronary artery disease and left ventricular dysfunction, significantly lowers the risk of heart failure, according to results of the SHIFT study (Systolic Heart failure treatment with the If inhibitor ivabradine Trial).
Ivabradine binds to If channels found in the sinus node, the heart's pacemaker. If channels generate an electrical impulse which causes the heart to contract so that blood can be pumped to the lungs and the rest of the body. By binding to these If channels, ivabradine thus slows the rate at which the heart beats.
Resting heart rate is known to be inversely related to prognosis in many cardiovascular diseases and is recognised to have independent prognostic value in heart failure. The SHIFT study was designed to investigate if ivabradine's inhibition of sino-atrial If current and had a beneficial effect in patients with a heart rate above 70 beats per minute.
“Heart failure is normally associated with high mortality risk”, said principal investigator Professor Michel Komajda, head of Cardiovascular and Surgical departments at the Pitié Salpetrière hospital in Paris. “Approximately 50% of patients die after five years, and they endure recurrent and lengthy hospitalisations as well as a decline in the quality of life. Despite the introduction of new treatments over the last 20 years resulting from significant medical advances, the prevalence of heart failure is actually increasing worldwide, particularly as people are living to an older age.”
More than 6500 patients with heart failure were enrolled in the trial, and randomised to either ivabradine or placebo. Heart failure was defined as NYHA class II - IV, left ventricular ejection fraction of 35% or less, and a prior hospitalisation for worsening heart failure within the previous 12 months. The patients were all receiving currently recommended heart-failure medication, and all had a heart rate of at least 70 bpm. Results showed that ivabradine significantly reduced the number of cardiovascular deaths or heart-failure hospitalisations (the primary endpoint of the study) by 18% (p<0.0001). It was also associated with a reduction of 26% in heart-failure events leading to hospitalisation or death. Average follow-up time was 23 months.
“This is a major finding,” said Professor Komajda. “The results have been achieved in addition to the effects of other medications. Heart failure and high heart rates are extremely common so it is very good news for patients and doctors that, even when using the best current drug treatment available, ivabradine further reduces the risk of death or hospitalisation by over 25%. Ivabradine has only one known cardiac action, so this opens a fascinating area of research. The SHIFT trial has demonstrated, for the first time, that reducing heart rate alone is beneficial for patients with heart failure.”
This press release accompanies both a presentation and an ESC press conference given at the ESC Congress 2010. The press release has been written and/or edited by the ESC from information provided by the investigator and does not necessarily reflect the opinion of the European Society of Cardiology. The content of the press release has been approved by the investigator.
About the European Society of Cardiology The European Society of Cardiology (ESC) represents more than 62,000 cardiology professionals across Europe and the Mediterranean. Its mission is to reduce the burden of cardiovascular disease in Europe.
About ESC Congress 2010 ESC Congress 2010 will take place from 28 August to 1 September at the Stockholmsmässan, Stockholm. Information on the scientific programme is available at http://spo.escardio.org/Search.aspx?eevtid=40 More information on ESC Congress 2010 is available from the ESC's press office at firstname.lastname@example.org.
Our mission: To reduce the burden of cardiovascular disease.
© 2020 European Society of Cardiology. All rights reserved.